GleamWall
中文EN

LIPO LIPELLA PHARMACEUTICALS INC.

Pharmaceutical Preparations · OTC · SEC CIK 1347242 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.4%
TTM net income YoY-25.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,387.9%
Net margin-1,367.4%
FCF margin—
EBITDA margin-1,387.2%

Returns

ROE-361.8%
ROA-236.4%
ROIC (approx.)—
Asset turnover0.17x

Leverage & solvency

Liabilities / assets36.7%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-24.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20242024-12-31FY20232023-12-31
Income statement
Revenue$536,357$449,617
R&D expense$3.61M$3.04M
SG&A expense$2.00M$2.16M
Operating income-$5.08M-$4.75M
Interest expense—$10,848
Pretax income-$5.02M-$4.62M
Net income-$5.02M-$4.62M
EBITDA-$5.08M-$4.74M
EPS (basic)-4.79-6.16
EPS (diluted)-4.79-6.16
Weighted avg. shares (diluted)1.05M750,383
Balance sheet
Cash & equivalents$2.18M$3.29M
Receivables$84,713$32,286
Current assets$2.62M$3.43M
PP&E, net$9,864$12,750
Total assets$2.67M$3.58M
Current liabilities$754,417$385,355
Total liabilities$754,417$432,726
Shareholders' equity$1.92M$3.14M
Shares outstanding1.21M756,743
Cash flow statement
Operating cash flow-$3.95M-$3.15M
Capital expenditure—$14,434
Free cash flow—-$3.16M
Investing cash flow—-$14,434
Financing cash flow$2.84M$1.34M
Depreciation & amortization$2,886$1,685

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.